251 related articles for article (PubMed ID: 26503519)
1. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
[TBL] [Abstract][Full Text] [Related]
2. Resource use and cost of hepatitis C-related care.
Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
4. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
Méndez-Sánchez N
Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
[No Abstract] [Full Text] [Related]
5. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
[TBL] [Abstract][Full Text] [Related]
6. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
7. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
[TBL] [Abstract][Full Text] [Related]
8. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
Mantravadi S
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
[No Abstract] [Full Text] [Related]
10. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
[TBL] [Abstract][Full Text] [Related]
11. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
12. Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.
Saab S; Jimenez M; Fong T; Wu C; El Kabany M; Tong MJ
Exp Clin Transplant; 2016 Feb; 14(1):66-71. PubMed ID: 26581477
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Hepatitis C Infection.
Stepanova M; Younossi ZM
Clin Liver Dis; 2017 Aug; 21(3):579-594. PubMed ID: 28689595
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
Hill LA; Delmonte RJ; Andrews B; Richards L; Soto R; Collier S; Kuo A; Cachay E
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1378-1383. PubMed ID: 29975243
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.
Hoshida Y; Shiratori Y; Omata M
Liver; 2002 Dec; 22(6):479-85. PubMed ID: 12445173
[TBL] [Abstract][Full Text] [Related]
17. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
18. Antiviral treatment for cirrhosis due to hepatitis C: a review.
Somasundaram A; Venkataraman J
Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
[TBL] [Abstract][Full Text] [Related]
19. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
